Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xuan Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7272-7271; OpenAlex author ID A5102878106. Sources: OpenAlex.

Their work

Papers
19 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 4 papers · 2023: 5 papers · 2024: 5 papers · 2025: 2 papers · 2026: 1 paper

Papers 19

  1. Interpretable Radiomics-Based Machine Learning for Non-Invasive Prediction of Tertiary Lymphoid Structure Status in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-10027511/v1↗
  2. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. Co-author DOI 10.1007/s00262-025-04205-x↗
  3. The association between long-term PM2.5 exposure and risk for pancreatic cancer: an application of social informatics. Co-author DOI 10.1093/aje/kwae271↗
  4. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00262-024-03648-y↗
  5. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. First author DOI 10.1007/s00262-024-03786-3↗
  6. BCL6 overexpression in CD4+ T cells induces Tfh-like transdifferentiation and enhances antitumor efficiency of CAR-T therapy in pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167346↗
  7. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Co-author DOI 10.1016/j.canlet.2024.216741↗
  8. Efficacy of Hyperthermic Intraperitoneal Chemotherapy Alone for Diffuse Peritoneal Carcinomatosis from Pancreatic Adenocarcinoma: A Single-Centre Retrospective… Co-author DOI 10.21203/rs.3.rs-4011964/v1↗
  9. Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1002/ijc.34468↗
  10. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. First author DOI 10.1136/jitc-2023-006698↗
  11. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. First author DOI 10.1186/s12876-023-02748-w↗
  12. Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. Co-author DOI 10.3390/cancers15030828↗
  13. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol30020126↗
  14. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  15. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  16. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-022-00411-9↗
  17. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/7353572↗
  18. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Co-author DOI 10.3390/cancers13153678↗
  19. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 17 shared papers, 2020–2025 · strength 2.77
  2. Yusheng Chen · 11 shared papers, 2022–2025 · strength 1.98
  3. Xuan Zou · 11 shared papers, 2022–2025 · strength 1.96
  4. Zhengjie Dai · 10 shared papers, 2022–2024 · strength 1.72
  5. Xu Wang · 10 shared papers, 2021–2025 · strength 1.66
  6. Yesiboli Tasiheng · 9 shared papers, 2022–2024 · strength 1.52
  7. Mingjian Ma · 8 shared papers, 2023–2025 · strength 1.50
  8. He Cheng · 8 shared papers, 2022–2025 · strength 1.39
  9. Chen Liu · 8 shared papers, 2022–2025 · strength 1.39
  10. Yu Yan · 4 shared papers, 2023–2025 · strength 0.76
  11. Long‐Yun Ye · 5 shared papers, 2020–2023 · strength 0.62
  12. Chen Liu · 3 shared papers, 2023–2024 · strength 0.55
  13. Zhenyu Liao · 4 shared papers, 2021–2023 · strength 0.53
  14. Tianjiao Li · 4 shared papers, 2020–2023 · strength 0.52
  15. Huaxiang Xu · 4 shared papers, 2020–2022 · strength 0.45
  16. Liang Liu · 4 shared papers, 2020–2022 · strength 0.45
  17. Yunzhen Qian · 3 shared papers, 2022–2023 · strength 0.44
  18. Weiding Wu · 3 shared papers, 2022–2023 · strength 0.43
  19. Kaizhou Jin · 3 shared papers, 2022–2023 · strength 0.43
  20. He Cheng · 2 shared papers, 2024 · strength 0.39
  21. Heli Gao · 3 shared papers, 2020–2022 · strength 0.33
  22. Wuhu Zhang · 3 shared papers, 2020–2022 · strength 0.33
  23. Wenquan Wang · 3 shared papers, 2020–2022 · strength 0.33
  24. Saimeng Shi · 2 shared papers, 2022–2023 · strength 0.30
  25. Qinglin Fei · 2 shared papers, 2022–2023 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.